Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT00113776
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal CancerMetastases
- Interventions
- Other: Best supportive care
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 463
- Registration Number
- NCT00113763
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Cancer
- Interventions
- Other: PI Discretion
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT00113789
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
Phase 2
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Registration Number
- NCT00113958
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 360
- Registration Number
- NCT00113945
Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Biological: Liatermin
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT00111982
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
Phase 4
Completed
- Conditions
- Chronic Renal FailureAnemia
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00111995
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT00111761
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Phase 2
Completed
- Conditions
- Colorectal CancerCarcinoma
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00111774
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00111449
© Copyright 2025. All Rights Reserved by MedPath